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Introduction: Since 2008, severe cases of emerging human adenovirus type 55 (HAdV-55) in immunocompetent
adults have been reported sporadically in China. The clinical features and outcomes of the most critically ill
patients with severe acute respiratory distress syndrome (ARDS) caused by HAdV-55 requiring invasive mechanical
ventilation (IMV) and/or extracorporeal membrane oxygenation (ECMO) are lacking.
Methods: We conducted a prospective, single-center observational study of pneumonia with ARDS in
immunocompetent adults admitted to our respiratory ICU. We prospectively collected and analyzed clinical,
laboratory, radiological characteristics, sequential tests of viral load in respiratory tract and blood, treatments
and outcomes.
Results: The results for a total of five consecutive patients with severe ARDS with confirmed HAdV-55 infection
were included. All five patients were immunocompetent young men with a median age of 32 years. The mean
time from onset to dyspnea was 5 days. Arterial blood gas analysis at ICU admission revealed profound hypoxia.
Mean partial oxygen pressure/fraction of inspired oxygen was 58.1. Mean durations from onset to a single-lobe
consolidation shown on chest X-rays (CXRs) and, from the first positive CXR to bilateral multilobar lung infiltrates,
were 2 days and 4.8 days, respectively. The viral load was higher than 1 × 108 copies in three patients and was
1 × 104 in one patient. It was negative in the only patient who survived. The mean duration for noninvasive positive
pressure ventilation (NPPV) failure and IMV failure were 30.8 hours and 6.2 days, respectively. Four patients received
venovenous ECMO. Four (80%) of the five patients died despite receiving appropriate respiratory support.
Conclusions: HAdV-55 may cause severe ARDS in immunocompetent young men. Persistent high fever, dyspnea
and rapid progression to respiratory failure within 2 weeks, together with bilateral consolidations and infiltrates, are
the most frequent clinical manifestations of HAdV-55-induced severe ARDS. Viral load monitoring may help predict
disease severity and outcome. The NPPV and IMV failure rates were very high, but ECMO may still be the respiratory
support therapy of choice.
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Human adenoviruses (HAdVs) are notorious pathogens
in people with compromised immune function and a
frequent cause of outbreaks of acute respiratory disease
among young children. Life-threatening adenoviral pneu-
monia has previously been documented among military
trainees, patients with AIDS and transplant recipients
[1-5]. Human adenovirus type 55 (HAdV-55), which
is emerging as a highly virulent pathogen for acute fatal
adenoviral pneumonia among immunocompetent adults
in China, has gained increasing attention [6]. HAdV-55 is
a newly identified, emergent acute respiratory disease
pathogen causing two recent outbreaks in China in 2006
[7] and in Singapore in 2005 [8]. In 2011, this pathogen
apparently re-emerged in Beijing, China, causing several
cases of severe community-acquired pneumonia [9]. This
pathogen was fully characterized by whole-genome se-
quencing [10]. Comparative studies showed that the ability
of HAdV to cause severe disease may relate to the sero-
types of HAdVs. Severe adenoviral pneumonia induced by
HAdV-55 has been reported to be more closely related
to severe cases compared to other serotypes (HAdV-3,
HAdV-7 and HAdV-14) [6].
Current knowledge of HAdV-55-induced severe acute
respiratory distress syndrome (ARDS) requiring invasive
mechanical ventilation and/or extracorporeal membrane
oxygenation (ECMO) support in immunocompetent adults
is derived from single case reports or relatively small,
single-center series. As a result, little information is avail-
able on HAdV-55 pneumonia complicated with severe
ARDS, the frequency of which is expected to increase in
the coming years. Here we describe the clinical features
and outcomes of five prospective cases of HAdV-55 pneu-
monia complicated with severe ARDS in immunocompe-
tent adults in our ICU.
Material and methods
Study population
Beginning in May 2012, a randomized trial of nonin-
vasive positive pressure ventilation (NPPV) in ARDS pa-
tients was carried out in our center (ClinicalTrials.gov
ID: NCT01585922). From May 2012 to April 2014, all
adult patients with ARDS caused by pneumonia who
were admitted to the respiratory ICU of Beijing Chao-Yang
Hospital were prospectively enrolled. Severe ARDS was
diagnosed according to the Berlin definition: (1) developing
within 1 week of a known clinical insult or new or worsen-
ing respiratory symptoms; (2) bilateral opacities not fully
explained by effusions, lobar and/or lung collapse, or
nodules; (3) respiratory failure not fully explained by car-
diac failure or fluid overload; (4) partial oxygen pressure/
fraction of inspired oxygen (PaO2/FiO2) ≤100 mmHg with
positive end-expiratory pressure (PEEP) ≥5 cmH2O;
and (5) a chest radiograph with three or four quadrantswith opacities. Patients with HAdV-55 infection and
severe ARDS who failed conventional NPPV and invasive
mechanical ventilation (IMV) were included in the ana-
lysis. This study was approved by the Institutional Review
Board of Beijing Chao-Yang Hospital (LLKYPJ2012031).
Data were analyzed anonymously. Each patient gave writ-
ten informed consent for their data to be used for research
and publication.
Clinical data collection
Clinical information collected by investigators with a
standardized data form included the following: demo-
graphic characteristics (age and sex), comorbidities,
clinical symptoms (fever, cough, sputum, dyspnea, chest
pain, rash, nausea, vomiting, abdominal pain, diarrhea
and headache), signs (body temperature, heart rate, respi-
ratory frequency, blood pressure and crackles in the
lungs), laboratory tests (whole-blood cell count and blood
chemistry) and microbiological findings and images of the
lung (chest X-ray (CXR) and computed tomography).
Concomitant medications, respiratory support, complica-
tions and outcomes were also recorded.
Microbiological tests
Patients’ specimens, including sputum, whole blood and
serum samples, were collected upon admission and dur-
ing hospitalization. Microbiological tests were performed
at the Department of Infectious Disease and Clinical
Microbiology in our center, and the detection methods
used were described in our previous report [6]. Common
viruses causing respiratory illness were screened using a
kit with 15 different viral assays. Serum samples were
used for Mycoplasma pneumoniae, Chlamydia pneumo-
niae and Legionella pneumophila antibodies. All patients
had their HAdV-55 infection confirmed by RT-PCR
assay. Partial sequences of the hexon gene were analyzed
to type the phylogeny of HAdV-55 strains. The adeno-
viral load was also performed on both respiratory speci-
mens and blood by multiplex RT-PCR assay.
Criteria for human adenoviral pneumonia
Viral pneumonia was diagnosed based on the presence
of HAdV detected in sputum or throat swab samples by
molecular methods.
Statistical analysis
Continuous variables were summarized as mean ± standard
deviation (SD) or median (interquartile range).
Results
During the study period, a total of eight patients diag-
nosed with HAdV infection and respiratory failure were
admitted to our ICU, and seven of them received a diag-
nosis of ARDS. Five consecutive patients with severe
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aAST, Aspartate aminotransferase (normal range = 10 to 42 U/L); CK, Creatine phosphokinase (normal range = 38 to 174 U/L); ECMO, Extracorporeal membrane oxygenation; HBDH, Hydroxybutyrate dehydrogenase
(normal range = 72 to 182 U/L); IMV, Invasive mechanical ventilation; LDH, Lactate dehydrogenase (normal range = 85 to 250 U/L); NPPV, Noninvasive positive pressure ventilation; P/F: Partial oxygen pressure/fraction
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to our ICU between April and July 2013. They were
included in the analysis. The other two patients had mild
ARDS and were infected with other types of HAdVs.Demographics
All five patients were immunocompetent young men
with a median age of 32 years (range, 28 to 40 years). All
of the patients shared a B blood type and came from the
same city: Baoding city, Hebei province, northern China.
All patients had no exposure to farm animals, corn or
hay. Patient 3 had tuberculosis pleuritis and received
antituberculosis therapy at ICU admission. His blood tests,
including the T-SPOT tuberculosis assay (Oxford Immu-
notec, Marlborough, MA, USA) and antibody of Mycobac-
terium tuberculosis, were negative.Clinical characteristics
Flulike symptoms, such as fever, cough and little sputum,
were commonly observed at the onset of illness. All
patients presented with a high fever, with a mean body
temperature of 39.5°C (range, 39.0°C to 40.0°C), which
persisted for 8 days (range, 6 to 11 days). Productive
cough was observed in two patients. Dull substernal chest
pain and rash were also observed in two patients. All
patients had dyspnea. The mean time from onset to dys-
pnea was 5 days (range, 1 to 10 days). After the onset of
dyspnea, patients usually progressed to respiratory failure
or hypoxemia. The mean time from onset to ICU admis-
sion was 9.6 days (range, 8 to 11 days) (Table 1).
All patients had tachypnea when admitted to the ICU,
with a mean rate of 43 breaths per minute (range = 38
to 52). Arterial blood gas analysis at ICU admission
revealed profound hypoxia, with a mean PaO2/FiO2 of
58.1 (range = 49 to 62.5). White blood cell counts were
low or in the normal range. All patients had elevated
serum aspartate aminotransferase (AST), lactate de-
hydrogenase (LDH) and hydroxybutyrate dehydrogen-
ase (HBDH) (Table 1). At admission, all patients’ levels
of immunoglobulin (serum immunoglobulins G and M)
and components C3 and C4 were in the normal range.Table 2 Humoral immunity and cell-mediated immunity on th
adenovirus type 55a
Patient Blood type T cells (n/ml) T4 cells (n/ml) T8-cells (n/ml)
Reference (770 to 2,040) (410 to 1,120) (240 to 880)
1 B 317 200 107
2 B NA NA NA
3 B 599 347 225
4 B 955 441 477
5 B 599 347 225
aIg, Immunoglobulin; NA, Not available; T cells, CD3-positive cells; T4 cells, Both CD3Four patients had lower than normal T-cell subset counts
(Table 2).
Radiographic features
CXRs revealed multiple bilateral lobar or segment
consolidation in the lungs of all five patients, and
radiographic lesions progressed rapidly after ICU admis-
sion (Figure 1). Three patients were examined by high-
resolution computed tomography (HRCT). Unilateral or
bilateral consolidations and infiltrates were found on
HRCT scans of all three of these patients. Consolidations
within a single lobe or several lobes with a clear border
and air bronchogram were the most common findings on
HRCT scans. Nodules, patches, pleural effusion, abscess
and a cavity were also seen visualized by HRCT (Figure 2).
The mean duration from onset to a single-lobe consolida-
tion on CXRs was 2 days (range = 1 to 5 days). The mean
duration from the first positive CXR to bilaterally multilo-
bar lung infiltrates was 4.8 days (range = 4 to 7 days).
Detection of adenoviruses by RT-PCR
All patients had HAdV-55 viremia. In four of the five
patients, it was first detected in endotracheal aspirate
(ETA) samples. The time between initial ETA sample
collection of adenoviruses and positive results for
HAdV-55 nucleic acid in the blood was 1 to 10 days
(Table 3). Virus DNA copies in ETAs were determined
for all patients during their ICU stay. The viral load was
higher than 1 × 108 copies in three patients and 1 × 104
in one patient. The viral load became negative in the only
patient who survived. In the four patients who did not
survive, DNA copies did not decrease, even with antiviral
therapy (Figure 3).
Respiratory support
Oxygenation was not maintained with conventional
NPPV or IMV support in any of the patients. The mean
duration until NPPV failure was 30.8 hours (range = 22
to 48 hours), and the mean time until IMV failure was
6.2 days (range 2 = to 13 days) (Table 1). Four patients
received venovenous ECMO to maintain oxygen satur-
ation, and one patient refused ECMO support and receivede immunocompetent adult infection with human
IgG (mg/dl) IgA (mg/dl) IgM (mg/dl) C3 (mg/dl) C4 (mg/dl)
(751 to 1,560) (82 to 453) (46 to 304) (79 to 152) (12 to 36)
858 142 163 102 20.4
NA NA NA NA NA
1260 136 64.2 86.8 26.4
1640 110 92.3 38.7 13.1
1260 136 64.2 86.8 26.4
- and CD4-positive cells; T8 cells, Both CD3- and CD8-positive cells.
Figure 1 Radiographic findings and their relationship to viral load monitoring in patient 4. (Picture 1) Radiographs show widespread
bilateral interstitial infiltrates at the onset of the disease. (Picture 2) The patient’s condition rapidly deteriorated within 3 days, and mechanical
ventilation was required. (Picture 3) The patient’s adenoviral infection progressed, so supplementary oxygen was given on day 3 of admission.
(Picture 4–8) Radiographs show gradual recovery with supportive therapy. Also shown are the trends of viral load detected with endotracheal
aspirates (ETAs) and their relationship to radiological changes.
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the oxygenation data of patients before and after venove-
nous ECMO support.
Antimicrobiological therapy and outcome
All patients received antiviral therapy, including acyclovir
(10 mg/kg, every 8 hours, intravenous drip), ganciclovir
(5 mg/kg, every 12 hours, intravenous drip) and ribavirin
(250 mg, twice daily, intravenous drip). Considering thatFigure 2 Dynamic changes on computed tomography scans for huma
tomography scans taken on day 1 show a nodular shadow in the right upp
and was surrounded by ground-glass opacity on day 4. The lesion was diff
the mediastinum window shows the formation of pulmonary abscess in th
Legionella, Staphylococcus and tuberculosis.bacterial coinfection may combine with a severe viral infec-
tion, broad-spectrum intravenous antibiotics were given to
all patients. Tests for bacterial pathogens were negative for
only one patient (Table 3). Four (80%) of the five pa-
tients died. Among the four patients receiving veno-
venous ECMO, only one patient survived. The other
four patients died due to ARDS, Aspergillus fumigatus
coinfection, septic shock and catheter-related bloodstream
infection due to Acinetobacter baumannii, respectively.n adenovirus type 55 pneumonia in patient 3. Chest computed
er lobe. The nodular shadow expanded dramatically within 3 days
use in both lung fields on day 8. A cavity was observed on day 23, and
e upper right lobe (red arrow). The lung abscess tested negative for




HAdV in blood tests
Highest PCT
level (ng/ml)
Bacteria Fungus G-test (pg/ml) Outcome Cause
of death
1 Sputum 2 5.66 Negative Negative <10 Death ARDS
2 Throat swab 1 4.67 Negative Aspergillus
fumigatus
<10 Death ARDS, IPA
3 Sputum 2 30.14 Acinetobacter
baumannii, Burkholderia
cepacia, Staphylococcus
Pneumocystis 164.7 Death Septic shock,
MODS
4 Sputum 10 1.58 Acinetobacter
baumannii
Negative <10 Survival –
5 Sputum 2 0.48 Acinetobacter
baumannii
Negative 256.1 Death CRBSI
aARDS, Acute respiratory distress syndrome; CRBSI, Catheter-related bloodstream infection; 1,3-beta-D-glucan, G-test (reference <20 pg/ml); HAdV, Human adenovirus;
IPA, Invasive pulmonary aspergillosis; MODS, Multiple organ dysfunction syndrome; PCT, Procalcitonin (reference <0.05 ng/ml).
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To the best of our knowledge, this is the first cohort
observational study on the clinical characteristics of
patients with severe ARDS caused by emergent HAdV-55
infection and also the first on the evaluation of a viral
load test for monitoring the reaction to therapy and for
prediction of patient outcome. The following are the
main findings of this study. (1) HAdV-55 may cause
severe ARDS in immunocompetent young men with
blood type B. All of our patients were from the same
city of Hebei province, northern China. (2) Persistent
high fever, dyspnea and rapid progression to respiratory
failure within 2 weeks, together with bilateral conso-
lidations and infiltrates at the same time, are the most
frequent clinical manifestations of severe HAdV-55-
induced ARDS. (3) Viral load monitoring may help predict
disease severity and patient outcome. (4) The NPPV and
IMV failure rates were very high, and ECMO may be the
last support method for this group of patients. (5) HAdV-
55-induced severe ARDS has a very high mortality rate
(80%) despite appropriate respiratory support.Figure 3 Changes in human adenovirus type 55 concentration
measured in endotracheal aspirates from all five acute
respiratory distress syndrome patients. Patient 4, whose viral
DNA copies in ETA became negative, was the only patient who
survived.Sporadic severe adenoviral infection in healthy adults
has historically been described for serotype 4 [11], serotype
7 [4,12] and, more recently, serotype 14 in the general
population and in military trainees [13,14]. HAdV-55 was
first completely characterized in Shaanxi, China [7] and
then reemerged in Hebei, a province close to Beijing,
where it caused several cases of acute respiratory disease
[9]. It was presumed that HAdV-55 was a recombinant
form of the B2 species of HAdV-14 and HAdV-11 [7,15]
due to its sharing a hexon gene with the HAdV-11 and
HAdV-14 chassis [16]. The results of our study show
that HAdV-55, as an emerging pathogen among immu-
nocompetent adults, may cause severe ARDS.
The prevalence of severe fatal adenoviral pneumonia
induced by HAdV-55 in our study is somewhat similar
to that described by Cao and colleagues [6]. All cases of
reported HAdV-55 in our study were from the same city:
Baoding, Hebei province, northern China. They occurred
between April and July 2013, just partly overlapping or
following the influenza epidemic. The patients with
severe disease also came from the same region and were
treated during a similar time period, which suggests that
HAdV-55 may be an important viral pathogen derived
from this region.
Our study results suggest that the following may be
clinical features of ARDS caused by HAdV-55: persistent
high fever, rapid progression of dyspnea, need for mech-
anical ventilation support, elevated AST level and rapid
progression from unilateral infiltrates to bilateral consoli-
dations. These clinical features are highly similar to those
of ARDS caused by other types of HAdV described in pre-
vious reports [6,9].
Recent studies have shown that the immune system
plays a crucial role in the clearance of HAdV viremia
and survival of the host [17]. Chen et al. reported that,
in the acute phase of HAdV-55 infection, patients with
severe disease may have high levels of dendritic cells
and Th17 cells [18]. In our study, the only patient who
Table 4 Oxygenation response to venovenous extracorporeal membrane oxygenation supporta





























Patient 1: ECMO manufacturer/model (4,150 rpm; MAQUET (Wayne, NJ, USA)), 5.2 L/min, 6.8 L/min, total of 8 days on ECMO
PSV 12 20 1 7.229 62.3 76.7 65 PA/C 10 20 0.3 7.406 37.5 74.7 93
Patient 2: No ECMO, HFOV = 4 Hz, △P = 70 cmH2O, Paw = 45 cmH2O
PA/C 18 10 0.8 7.267 81 76.3 94 No – – – – – – –
Patient 3: ECMO manufacturer/model (3,950 rpm; MAQUET (Wayne, NJ, USA)), 5.0 L/min, 5.0 L/min, total of 6 days on ECMO
PA/C 12 20 1 7.25 66.4 75.4 90 PA/C 10 18 0.4 7.517 41.2 71.5 96
HFOV = 4.5 Hz, △P = 65 cmH2O, Paw = 26 cmH2O
Patient 4: ECMO manufacturer/model (3,740 rpm; MAQUET (Wayne, NJ, USA)), 4.38 L/min, 4.0 L/min, total of 2 days on ECMO
SIMV 24 10 1 7.44 38 44 76 PA/C 10 14 0.35 7.441 37.5 89.6 96.8
Patient 5: ECMO manufacturer/model (3,340 rpm; MAQUET (Wayne, NJ, USA)), 4.9 L/min, 4.5 L/min, total of 13 days on ECMO
PA/C 16 18 1 7.347 74.2 80.2 83 PA/C 12 14 0.3 7.485 40.8 103 96
HFOV = 4 Hz, △P = 65 cmH2O, Paw = 30 cmH2O
aECMO, Extracorporeal membrane oxygenation; FiO2, Fraction of inspired oxygen; HFOV, High-frequency oscillatory ventilation; PA/C, Pressure assist/control; PaCO2, Partial pressure of carbon dioxide; PaO2, Partial pres-
sure of oxygen; Paw, Airway pressure; PEEP, Positive end-expiratory pressure; Pi, Initial pressure; PS, Sustained pressure; PSV, Pressure support ventilation; SIMV, Synchronized intermittent mechanical ventilation; SpO2,
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Three of the five patients had relatively low T-cell counts
when admitted. Our results suggest that these three
patients may have been relatively immunocompromised
and that a lower T-cell count may be a risk factor for
HAdV-55 infection in young adults.
HAdV-55 DNA was previously reported in 41.2% of
patients with severe infection [18]. In our study, HAdV-
55 DNA was detected and monitored in all patients with
severe ARDS. The initial, and trend of, viral load that
presented as HAdV-55 DNA copies in the respiratory
tract samples and blood may suggest the severity of
infection and may predict both the reaction to therapy
and patient outcome.
The use of mechanical ventilation and ECMO in
patients with ARDS caused by HAdV-55 has not been
detailed in previous studies. In our cohort, we found that
severe HAdV-55 infection could cause a rapid progres-
sion of respiratory failure, with a very high failure rate
for NPPV and IMV. This failure rate may be a result of
the large area of consolidation that induced a severe
shunt in the lung, which may lead to lack of response to
positive pressure ventilation. For patients with severe
ARDS, ECMO should be considered a better choice for
oxygenation.
Our study has limitations. It is an observational study
with no comparison group, so the difference between
the severe and modest infections could not be clarified
in terms of immune status, clinical features, radiological
findings, viral load and treatment effects on respiratory
support and antiviral therapy. Sequential dynamic ana-
lysis is needed to determine the relationship between
HAdV-55 viremia and treatment response.
Conclusions
Our data provide new insight into the clinical features of
HAdV-55 infection in patients with severe ARDS.
HAdV-55 may cause severe ARDS in immunocompetent
young men. Persistent high fever, dyspnea and rapid pro-
gression to respiratory failure within 2 weeks, together
with bilateral consolidations and infiltrates during the
same period, are the most frequent clinical manifesta-
tions of severe HAdV-55-induced ARDS. Viral load
monitoring may help predict disease severity and patient
outcome. NPPV and IMV failure rates were very high,
and thus ECMO may be a better choice of respiratory
support in this group of patients. HAdV-55-induced
severe ARDS has a very high mortality rate (80%) despite
appropriate respiratory support.
Key messages
 HAdV-55 infection may be a cause of severe ARDS
in immunocompetent young male adults. Persistent high fever, dyspnea, rapid progression to
respiratory failure within 2 weeks, together with
bilateral consolidations and infiltrates during the
same period, are the most frequent clinical
manifestations of severe HAdV-55-induced ARDS.
 Viral load monitoring may be helpful in predicting
patients’ disease severity and outcome.
 NPPV and IMV failure rates were very high, and
thus ECMO may be a better choice for respiratory
support in this group of patients.
 HAdV-55-induced severe ARDS has a very high
mortality rate of 80% despite appropriate
respiratory support.
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